Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC

Sponsor
Tel-Aviv Sourasky Medical Center
Study ID
NCT00268684
Phase
PHASE3
Status
Unknown

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Neoplasm Metastasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The objectives of the study is to determine if either temozolomide or erlotinib combined with WBRT and SRS improves survival as compared to WBRT and SRS alone.Ptients with histologically confirmed NSCLC with the presence of 1-3 intraparenchymal brain metastases will be randomized to 3 arms. All of the patients will receive WBRT and SRS. The patients of the arm 1 will receive radiation treatment only, the arm 2 patients will be treated with temozolomide and arm 3 patients will receive erlotinib

Key Dates

First listed
Dec 22, 2005
Start date
May 31, 2005
Status verified
Dec 2005

Study Design

Enrollment
381 participants

Primary Outcome Measure

survival

Central Contacts

Related Studies